BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20385457)

  • 1. Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer.
    Turaka A; Li T; Nicolaou N; Lango MN; Burtness B; Horwitz EM; Ridge JA; Feigenberg SJ
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):65-70. PubMed ID: 20385457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional relapse after intensity-modulated radiotherapy for head-and-neck cancer.
    Duprez F; Bonte K; De Neve W; Boterberg T; De Gersem W; Madani I
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):450-8. PubMed ID: 20381266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
    Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distant metastases in head-and-neck squamous cell carcinoma treated with intensity-modulated radiotherapy.
    Yao M; Lu M; Savvides PS; Rezaee R; Zender CA; Lavertu P; Buatti JM; Machtay M
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):684-9. PubMed ID: 22169673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.
    Villeneuve H; Després P; Fortin B; Filion E; Donath D; Soulières D; Guertin L; Ayad T; Christopoulos A; Nguyen-Tan PF
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1866-71. PubMed ID: 21497452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of intensity-modulated radiotherapy for head and neck cancers in routine practice.
    Bednarek C; Nguyen TV; Puyraveau M; Bonnet É; Lescut N; Azélie C; Miny J; Mauvais O; Maurina T; Tochet F; Bosset JF; Thariat J; Sun XS
    Cancer Radiother; 2017 Feb; 21(1):21-27. PubMed ID: 28034680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer.
    Mok G; Gauthier I; Jiang H; Huang SH; Chan K; Witterick IJ; O'Sullivan B; Waldron JN; Bayley AJ; Cho BC; Cummings BJ; Dawson LA; Hope AJ; Kim JJ; Ringash J
    Head Neck; 2015 May; 37(5):655-61. PubMed ID: 24590756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma.
    Dirix P; Nuyts S
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1373-80. PubMed ID: 20362402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
    McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
    Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.
    Chen AM; Li BQ; Lau DH; Farwell DG; Luu Q; Stuart K; Newman K; Purdy JA; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1026-32. PubMed ID: 20231073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience.
    Katsoulakis E; Riaz N; Hu M; Morris L; Sherman E; McBride S; Lee N
    Laryngoscope; 2016 Mar; 126(3):620-6. PubMed ID: 26597398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unknown primary head and neck cancer treated with intensity-modulated radiation therapy: to what extent the volume should be irradiated.
    Lu H; Yao M; Tan H
    Oral Oncol; 2009 Jun; 45(6):474-9. PubMed ID: 18804408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of outcomes using intensity-modulated radiation therapy and 3-dimensional conformal radiation therapy in treatment of oropharyngeal cancer.
    Lohia S; Rajapurkar M; Nguyen SA; Sharma AK; Gillespie MB; Day TA
    JAMA Otolaryngol Head Neck Surg; 2014 Apr; 140(4):331-7. PubMed ID: 24557509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the planning target volume in the treatment of head and neck cancer with intensity-modulated radiotherapy: what is the appropriate expansion margin in the setting of daily image guidance?
    Chen AM; Farwell DG; Luu Q; Donald PJ; Perks J; Purdy JA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):943-9. PubMed ID: 20932680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
    Peñagarícano JA; Moros EG; Ratanatharathorn V; Yan Y; Corry P
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1369-75. PubMed ID: 19625138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
    de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer.
    Maguire PD; Papagikos M; Hamann S; Neal C; Meyerson M; Hayes N; Ungaro P; Kotz K; Couch M; Pollock H; Tepper J
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1081-8. PubMed ID: 20378262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy.
    Li B; Li D; Lau DH; Farwell DG; Luu Q; Rocke DM; Newman K; Courquin J; Purdy JA; Chen AM
    Radiat Oncol; 2009 Nov; 4():52. PubMed ID: 19909531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.